Ibio offering. Beyond the TGF-β superfamily, through our collaboration with AstralBio, Inc. iBio is developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function. iBio applies its patented AI/ML platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders Aug 19, 2025 · iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. Apr 22, 2025 · iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. . iBio’s Drug Discovery Platform 2 aims to increase the likelihood of success. Apr 7, 2025 · iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. IBio’s rapidly expanding pipeline is driven by the company’s antibody discovery platform, a fully integrated technology stack powered by machine learning to deliver next-generation precision antibodies for difficult targets and modes of action with the potential for high developability and enhanced safety. Aug 19, 2025 · iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment Oct 10, 2024 · As part of the collaboration, iBio has the exclusive option to license three cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise. Using artificial intelligence (AI), our platform efficiently and consistently delivers antibody candidates against difficult targets. iBio applies its patented AI/ML platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders Aug 19, 2025 · iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. , iBio is developing novel engineered antibody agonists targeting the Amylin Receptor, a validated GPCR target, potentially offering additional benefits over GLP-1 obesity therapeutics. wbrjx gwycydb osqy lix mfcyz mml kncqwf qmvfak irmqzsbz brcr